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Introduction. The aim of this study was to investigate the eﬀect of bezaﬁbrate as a pan-PPAR agonist on angiogenesis and serum
nitrite, the main metabolite of nitric oxide (NO), vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-
2) concentrations in hindlimb ischemia model of normal and type I diabetic rats. Methods. 28 male Wistar rats were divided
into control and diabetic groups. Then, all rats underwent unilateral hindlimb ischemia. After recovery, they were randomly
assigned to one of the following experimental groups: (1) control; (2) control+bezaﬁbrate (400mg/kg/day); (3) diabetic; (4)
diabetic+beztaﬁbrate. After three weeks, blood samples were taken and capillary density was evaluated in the gasterocnemius
muscle of ischemic limb. Results. Bezaﬁbrate increased capillary density and capillary/ﬁber ratio in ischemic leg of diabetic and
control rats (P<0.05). Serum VEGF and VEGFR-2 concentrations did not alter after bezaﬁbrate administration, however, serum
nitriteconcentrationwassigniﬁcantlyhigherinbezaﬁbrate-treatedgroupsthannon-treatedgroups(P<0.05).Discussion.Itseems
that bezaﬁbrate, as a pan PPAR agonist, restores angiogenesis in hindlimb ischemic diabetic animals and is useful for prevention
and/or treatment of peripheral artery disease in diabetic subjects.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are
ligand-inducible transcription factors that regulate expres-
sion of genes involved in some biological eﬀects including
lipid metabolism, inﬂammatory responses, and glucose
homeostasis [1]. There are three isotypes of PPAR super-
family: PPARα,P P A R β,a n dP P A R γ. Today, PPAR agonists
have clinical importance in management of dyslipidemia
( s u c ha sc l o ﬁ b r a t e ,aP P A R α agonist) and reducing insulin
resistance and antidiabetic activity (such as rosiglitazone,
aP P A R γ agonist). Bezaﬁbrate, a PPARα agonist, is high-
aﬃnity ligand of PPARγ and PPARβ a n di sc o n s i d e r e da s
a pan-PPAR agonist [2, 3]. Bezaﬁbrate is more eﬃcient in
reducing body weight and blood glucose than fenoﬁbrate
in overweight mice fed with high-fat diet [4]. It also raises
HDL, reduces triglyceride, and improves insulin sensitivity
in diabetic subjects [5, 6].
Diabetes is associated with several cardiovascular abnor-
malities including abnormal angiogenesis [7]. Enhanced or
insuﬃcient angiogenesis plays a role in some complications
of diabetes including diabetic retinopathy or impaired
wound healing, respectively [8]. In recent years, it is sug-
gestedthatPPARsmaybeinvolvedinregulatingangiogenesis
[9]; however, the role of these receptors in angiogenesis
process still remained unclear [9].
Angiogenesis is a growth of new blood vessels from
preexisting vessels and stimulated by tissue hypoxia via
activation of hypoxia-inducible factor [10]. Then, activation
oftranscriptionofseveralangiogenicfactorsoccurs.Vascular
endothelial growth factor (VEGF) is a 45kD glycopro-
tein which is involved in physiological and pathological
angiogenesis [11]. VEGF has two tyrosine kinase receptors:
VEGFreceptor-1(VEGFR-1)andVEGFreceptor-2(VEGFR-
2). VEGFR-2 is the predominant eﬀector of proangiogenic
signaling in angiogenesis process [12]. Nitric oxide (NO) is
anotherangiogenicfactorwhichplaysakeyroleinangiogen-
esis [13] especially in postischemic revascularization [14].
Since peripheral artery disease is one of the most important
complications of diabetes, this study aimed to investigate the2 International Journal of Peptides
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Figure 1: Serum nitrite concentration (μmol/lit) before (pre) and
after (post) experiment in the study groups. n = 7 each group.
eﬀect of bezaﬁbrate as a pan-PPAR agonist on angiogenesis
in hindlimb ischemia model of normal and type I diabetic
rats.
2.MaterialsandMethods
2.1. Animals. In total, 28 male Wistar rats (Pasteur Institute
of Iran) at 8–10 weeks old were studied. The animals were
kept two per cage in animal room with 12h light/dark cycle
a n dr o o mt e m p e r a t u r eb e t w e e n2 0a n d2 5 ◦C and had free
access to water and food adlibitum.Theethicalcommitteeof
the authors’ institution approved all experimental protocol.
2.2. Hindlimb Ischemia Model and Treatment Groups. Dia-
betes was induced by single dose of intraperitoneal injec-
tion of streptozotocin (55mg/kg). Control groups received
normal saline injection with the same volume. After 48h,
blood glucose levels were measured and the animals with
blood glucose level higher than 16.7mmol/lit were con-
sidered as diabetic [15]. Then, all rats were anaesthetized
by intraperitoneal injection of ketamine (75mg/kg) and
xylazine (7.5mg/kg) and underwent unilateral hindlimb
ischemia as previously described [16, 17]. For this purpose,
femoral artery and all major branches were closed and
excised. Then, the skin was closed with 3–0 surgical suture.
Diabetic and control groups were randomly divided into
two groups: treated with bezaﬁbrate and nontreated groups.
Bezaﬁbrate was dissolved in corn oil and administered
400mg/kg/day by gavage on day after operation [18]. Non-
treated groups received the vehicle. The rats were assigned
to one of the following experimental groups: (1) control; (2)
control + bezaﬁbrate; (3) diabetic; (4) diabetic + bezaﬁbrate
(n = 7 each). Before experiment (after randomization)
and after three weeks of treatment, blood samples were
taken and centrifuged at 3000c/s for 20 minutes. Serum
sampleswerepoured in Eppendorf tubesand saved at −70◦C
for further analysis of serum nitrite, VEGF, and VEGFR-2
concentrations.
2.3. Serum Nitrite, VEGF, and VEGFR-2 Measurements. The
serum concentration of nitrite, the main metabolite of NO,
was assayed by griess reagent method (Promega Corp, USA)
according to the manufacture’s instruction. The serum levels
of VEGF and VEGR-2 were measured using a sandwich
enzyme immunoassay kit (R&D systems, USA). Serum lipids
and blood glucose concentrations were measured using
commercially available kits.
2.4. Measurement of Capillary Density. The animals were
sacriﬁed by cervical dislocation at 21 days after treatment,
and capillary density was evaluated in the gasterocnemius
muscle of ischemic limb. The samples were embedded in
paraﬃn. Sections with 5μm thickness were stained with
rat monoclonal antibody against murine CD31 (Abcam,
Cambridge, UK). Capillary endothelial cells were identiﬁed
by CD31-positive cells and counted by a light microscope.
Ten microscopic ﬁelds (×400) from three diﬀerent sections
in each tissue block were randomly selected, and the
number of capillaries was counted by two blinded observers.
Capillary density was expressed as the number of capillaries
per square millimeter. Capillary/muscle ﬁber ratio was also
expressed, because muscle atrophy or interstitial edema may
overestimate or underestimate capillary density.
2.5. Statistical Analysis. All data are expressed as mean ±
SE. The Kolmogorov-Smirnov test for evaluation of normal
distribution of data. One-way ANOVA using Tukey’s post
hoc test was used to compare data between groups. Bivariate
correlations were calculated using Pearson’s correlation
coeﬃcient. Paired data was analyzed by paired t-test. P value
less than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Serum Lipid Proﬁle. All of the animals were survived
after induction of hindlimb ischemia. Serum lipid proﬁle
of experimental groups is shown in Table 1. Our results
showed that bezaﬁbrate did not change the plasma levels
of triglyceride (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and
total cholesterol (TC) in control and diabetic animals (P>
0.05).
3.2. Serum Nitrite Concentration. Figure 1 illustrates serum
nitrite concentration in all experimental groups. Results
showed that diabetic animals had lower serum nitrite
concentration than control group (P = 0.08). Also, the
diabetic animals who received bezaﬁbrate had higher serum
nitrite concentration than non-treated group (P<0.05).
3.3. Serum VEGF and VEGFR-2 Concentrations. Results
showed that there were no signiﬁcant diﬀerences in serum
VEGF and VEGFR-2 concentrations between diabetic and
control groups (P>0.05). Bezaﬁbrate administration didInternational Journal of Peptides 3
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Figure 2: Serum VEGF (a) and VEGFR-2 (b) concentrations in experimental groups. n = 7 each group.
Table 1: Serum lipid proﬁle before and after experiments. There were no signiﬁcant diﬀerences between bezaﬁbrate-treated and nontreated
groups (P>0.05).
Groups Total cholesterol (mg/dL) Triglyceride (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL)
Before After Before After Before After Before After
Control 66.00 ±6.79 84.40 ±8.74 93.16 ±6.72 73.40 ±5.88 28.33 ±4.19 44.66 ±5.01 25.56 ±1.94 28.52 ± 3.66
Control + bezaﬁbrate 84.40 ±8.74 79.80 ±9.35 63.40 ±5.88 87.00 ±6.77 44.66 ±5.01 33.60 ±4.24 19.63 ±2.44 20.76 ± 2.56
Diabetic 70.33 ±5.44 72.25 ±7.06 81.80 ± 15.02 71.25 ±12.37 26.00 ±3.55 33.40 ±2.76 19.63 ±2.44 20.76 ± 2.56
Diabetic + bezaﬁbrate 72.25 ±7.06 85.42 ±9.18 71.25 ± 12.37 93.75 ±10.43 33.40 ±2.76 37.14 ±4.74 21.16 ±2.78 24.20 ± 5.67
Data are expressed as mean ± SE.
Control Diabetic Control +
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Diabetic +
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Figure 3: Eﬀect of pan-PPAR agonist, bezaﬁbrate, on capillary
density/ﬁber ratio of hindlimb ischemia. n = 7 each group.
not signiﬁcantly change serum VEGF and VEGFR-2 values
in control and diabetic animals (P>0.05) (Figure 2).
3.4. Capillary Density. Figure 3 illustrates that the capillary
density/muscle ﬁber ratio in ischemic gastrocnemius muscle
of diabetic animals was signiﬁcantly lower than control
(P<0.05). Capillary/ﬁber ratio was also signiﬁcantly lower
in diabetic than control group (P<0.05). Bezaﬁbrate
signiﬁcantly restored capillary density and capillary/ﬁber
ratio in both diabetic and control groups (P<0.05).
Samples of immunohistochemical stained with anti-CD31
monoclonal antibody are shown in Figure 4.
3.5. Correlation Analysis. In the correlation analysis, we
found that capillary density in skeletal muscle tissue was
positively correlated with the serum nitrite level (r = 0.55).
4. Discussion
Diabetes is one of the most important risk factors for
development of peripheral artery disease [19], and thera-
peutic angiogenesis has been considered to improve tissue
perfusion in these subjects. In this study, we found that
neovascularization in hindlimb ischemic diabetic animals
was lower than control and bezaﬁbrate signiﬁcantly restored
capillary density and serum nitrite level in diabetic hindlimb
ischemic rats.
Among many genes induced after hypoxia to increase
new blood vessel growth, the VEGF family genes and
NO synthase are most important [9]. VEGF is one the
most important growth factors which aﬀects all aspects of
angiogenesis including matrix degradation and endothe-
lial cell migration and proliferation [8, 11, 20]. VEGFR-
2 is expressed primarily on endothelial cells and is the
predominant eﬀector of angiogenesis signaling [12]. The
presentstudyshowedthatbezaﬁbrateadministrationdidnot
change serum VEGF and VEGFR-2 concentrations, however,
signiﬁcantly increased serum nitrite, the main metabolite of
NO,level.NOhasakeyroleinphysiologicalandpathological
neovascularization process [13, 21]. NO regulates endothe-
lial cell proliferation, migration, and apoptosis [22, 23]. It4 International Journal of Peptides
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Figure 4: Representative photographs of immunohistochemical staining (×400) with anti-CD31 monoclonal antibody in experimental
groups. Arrows indicates CD31-positive cells.
also mediates the angiogenic response to VEGF or other
angiogenic factors [24].
In the recent years there has been increasing evidences
that PPARs are involved in regulation of angiogenesis;
however, the exact role of these receptors still remained
controversial [9, 25, 26]. Bezaﬁbrate is a high-aﬃnity ligand
for all three isoforms of PPARs and considered as a pan-
PPAR agonist [2, 3]. In clinical studies, antidiabetic and
antihyperlipidemic eﬀects of bezaﬁbrate have been docu-
mented [5, 6]. It also prevents ischemic heart injury and
reduces coronary artery disease [27, 28]. In the present
study, we found that bezaﬁbrate restored angiogenesis in
hindlimb ischemic diabetic rats. According to our knowl-
edge, this is the ﬁrst study in this model of angiogenesis in
diabetic animals. Balance between pro- and antiangiogenic
factors regulates angiogenesis process. PPARs may modulate
angiogenesis through the action of some growth factors
and cytokines [9]. Biscetti et al. suggested that the eﬀect of
PPARs on angiogenic process is dependent on VEGF activity
[29]. In the present study, we found that bezaﬁbrate did
not signiﬁcantly alter serum VEGF and VEGFR-2 concen-
trations in diabetic animals. Instead, it increased serum NO
level in diabetic group. A clinical study in patients with
metabolic syndrome demonstrated that bezaﬁbrate reduced
incidence of myocardial infarction [3]. The importance
of NO in angiogenesis in hindlimb ischemia model has
been documented in previous studies [14, 17]. Thus, with
considering the positive correlation between serum nitrite
level and capillary density, our results suggest the possible
involvement of NO pathway in increased neovascularization
after bezaﬁbrate administration.
In conclusion, while bezaﬁbrate, as pan-PPAR agonist,
restores angiogenesis in hindlimb ischemic diabetic animals
and may be beneﬁcial for prevention or treatment of periph-
eral artery disease in diabetic subjects, further studies for
evaluation of its impact on other angiogenic, antiangiogenic,
and endothelial markers, especially in long-term use in
human, are required.International Journal of Peptides 5
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